2024
Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?
Hu J, Schwann A, Tan J, Nuqali A, Riello R, Beasley M. Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter? Heart Failure Clinics 2024, 20: 373-386. PMID: 39216923, DOI: 10.1016/j.hfc.2024.06.004.Peer-Reviewed Original Research
2023
Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?
Hu J, Schwann A, Tan J, Nuqali A, Riello R, Beasley M. Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter? Cardiology Clinics 2023, 41: 511-524. PMID: 37743074, PMCID: PMC12070421, DOI: 10.1016/j.ccl.2023.06.007.Peer-Reviewed Original ResearchConceptsReduced ejection fractionEjection fractionHeart failureChronic kidney diseaseQuadruple therapyTarget dosingTherapy initiationAtrial fibrillationKidney diseaseSpecial populationsMedicationsConventional sequencesTolerabilityBradycardiaPatientsFailureFibrillationDosingTherapyInitiationDiseaseDosesGDMT
2022
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication prices
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistanceIs it time for quadruple therapy to be first line?
Laine L. Is it time for quadruple therapy to be first line? 2003, 347-351. DOI: 10.1007/978-94-017-1763-2_36.ChaptersProton pump inhibitorsTriple therapyEradication ratePylori infectionCombination of PPIBismuth-based triple therapyPooled eradication ratesH. pylori infectionHelicobacter pylori infectionQuadruple therapyEarly therapyCurrent therapiesPump inhibitorsSeparate medicationsTherapyFirst lineInfectionStudies2–4Medications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply